Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$27.85
-$0.86(-3.93%)
At close: 4:00 PM EST
$27.85
-$0.86(-3.93%)
Day’s Range― - ―
52-Week Range$14.65 - $37.27
Previous CloseN/A
Volume20.02K
Average Volume (3M)225.72K
Market Cap
$496.97M
Enterprise Value$371.51M
Total Cash (Recent Filing)$243.18M
Total Debt (Recent Filing)$9.13M
Price to Earnings (P/E)―
Beta3.00
Next Earnings
Aug 07, 2026EPS Estimate
-1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.03
Shares Outstanding15,801,901
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.71
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$80.00Price Target Upside187.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA low debt-to-equity ratio and substantial equity/assets provide durable funding flexibility for a clinical-stage biotech. This reduces near-term refinancing pressure, supports continued R&D and trial execution, and materially improves the firm's ability to manage multi-year development timelines despite ongoing burn.
Registrational Progress And Positive Long-term DataCompletion of registrational dosing plus durable, multidomain functional gains in Phase 1/2 materially de-risks the clinical pathway. Sustained improvements through 30 months and an absence of treatment-related serious events bolster the probability of a successful BLA and long-term therapeutic value for NGN-401.
Commercial Leadership Hire And Governance AlignmentBringing in an experienced CCO and formalizing management on the board signal deliberate build-out of commercial and launch capabilities. This durable organizational shift strengthens launch planning, payer engagement and commercialization execution should NGN-401 achieve approval, lowering execution risk.
Bears Say
Large And Widening LossesSubstantially increasing net losses indicate elevated development and operating spend with no offsetting revenue. Persistent negative profitability reduces internal funding capacity and creates ongoing reliance on external financing, which can dilute shareholders and constrain long-term strategic optionality.
High Cash Burn And Negative Free Cash FlowDeeply negative operating and free cash flow erode treasury reserves and increase the likelihood of near-term capital raises. This structural cash consumption pattern creates financing risk, potential dilution, and can force trade-offs between development programs, slowing pipeline advancement.
Single-asset Concentration And Pre-commercial RiskRelying principally on one lead gene-therapy program concentrates regulatory, clinical and commercial risk. A single registrational outcome will disproportionately determine company prospects; small trial cohorts and single-arm designs increase outcome variability and sustain binary, long-duration risk to enterprise value.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $14.65 and its highest was $37.27 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $496.97M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Aug 07, 2026 which is in 37 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on May 12, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.296 by -$0.094.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.43.
How many shares outstanding does Neurogene have?
Neurogene has 15,801,901 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.296. Following the earnings report the stock price went up 3.424%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.00 (187.25% Upside)
$80.00 (187.25% Upside)
Insider Transactions
Sold Shares
Worth $147.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.14%
12-Months-Change
Fundamentals
Return on Equity
-37.88%
Trailing 12-Months
Asset Growth
-16.54%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$80.00
▲(187.25% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
9.37% Insiders
8.34% Mutual Funds
69.14% Other Institutional Investors
3.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---